Neuronal gene regulation and chromatin.
The Heller Lab studies the gene regulatory mechanisms that underlie psychiatric disease. To approach this problem, we apply preclinical mouse paradigms of drug addiction and depression to define functionally relevant histone modifications and transcription factors. Because the syndromes of addiction and depression persist long after cessation of the insult, chromatin remodeling is an attractive mechanism for such long-lasting effects and presents an intriguing target for therapeutic intervention. We use high-throughput sequencing and bioinformatic approaches, including machine learning, to identify genes at which drug- or stress-regulation of the epigenome correlates with changes in gene expression. Using novel epigenetic editing tools, we then target individual modifications and examine their causal relevance to transcription and behavior. This ‘bottom-up’ approach allows direct elucidation of the causal relevance of epigenetic remodeling in the brain.
Kiara Rodriguez passed her preliminary exam and is now officially a thesis student in the CAMB G&E program. Congratulations, Kiara!
Congratulations to Liz Heller (@EAHellerPhD) on her promotion to Associate Professor with tenure!! It's a true pleasure and honor to work with such an amazing scientist and colleague. Congrats Liz. https://t.co/0CeUeiV2Tm pic.twitter.com/t7QTIoEGql
— E. John Wherry (@EJohnWherry) May 5, 2023
Dr. Heller was a contributing author in a published paper, titled “Mapping PTBP2 binding in human brain identifies <SYNGAP1> as a target for therapeutic splice switching,” in Nature Communications. Congratulations, Dr. Heller!
Dr. Heller is a faculty leader of the Trainee Advocacy Alliance (TAA), a collaborative group of Biomedical Graduate Studies (BGS) graduate students, Biomedical Postdoctoral Program (BPP) post-docs, and Penn faculty members who are committed to creating, nurturing, and maintaining a Penn biomedical research community that embodies inclusivity, diversity, and equity.